

OpSens focuses mainly on cardiology, offering an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcomes of patients with coronary artery disease. OpSens has also developed a pressure guidewire to aid in valve positioning in the treatment of aortic valve stenosis (TAVR) - the fastest-growing segment in structural cardiology. OpSens is also involved in industrial activities.

Cornerstone for OpSens' Growth

Business Growth

- Coronary artery disease and TAVR products supported by key opinion leaders and medical publications
- Cleared by U.S. FDA and Health Canada
- Supply contract with Abiomed extended to 2028
- Agreements with major U.S. group purchasing organizations, covering 90% of hospitals, in the U.S.
- Technology fosters business partnerships

Innovation

- SavvyWire - major opportunity for TAVR
Product cleared by Health Canada and U.S. FDA
CE Mark expected end of 2023.
- Optimization of current products (performance & margin)


Financial Performance

- Continued growth in revenues and margins

Shares outstanding **115 M**

Number of employees **300**

OPS Revenue



Legs for Growth and Value Creation

Based on Fidela,TM its second-generation fiber optic sensor, OpSens has designed the OptoWire, a guidewire that aims at improving the clinical outcomes of patients with coronary artery disease. The OptoWire has been used in 250,000 patients worldwide.

OpSens is capitalizing on the expertise acquired in the development of its first product for cardiology to extend its activities to structural cardiology, with the SavvyWire, a pressure guidewire to assist in the positioning of valves in TAVR procedures - currently the fastest growing segment in structural cardiology. The global TAVR market is expected to reach 400,000 procedures in 2025 and 600,000 in 2030.

OpSens' technology can be adapted to different applications, allowing the Company to enter business partnerships in various profitable markets.

**Coronary Artery Disease
Market: \$1 Billion
in 2025¹**

Product : OptoWire

Aims at improving the clinical outcomes of patients with coronary artery disease
Used in over 250,000 patients
Medical publications
Support from key opinion leaders
Worldwide sales channels

**Aortic Valve Stenosis
Market: \$ 5 Billion
in 2021²**

Product : SavvyWire

Transcatheter aortic valve replacement (TAVR)
Fastest growing segment
in structural cardiology
Approved by Health Canada
Cleared by U.S. FDA
CE Mark expected by the end of 2023

**Business Partnerships
Sensor can be used in
several applications,
markets**

Medical



Industrial



1. Growth projected in Global FFR Market 2016-2020


2. Global TAVR/Implantation, Kenneth Research, 2018

Structural Cardiology - The fastest growing segment in cardiology
OpSens entering market that will reach \$8 billion in 2025³

OpSens' SavvyWire is the world's first and only sensor-guided TAVR solution. It provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access. Approved by U.S. FDA and Health Canada, used in select locations in Canada and the U.S.

OpSens has what it takes to enter the market quickly

PARTNER 3 & EVOLUT studies support TAVR for all-comers population.



³. Global TAVR/Implantation, Kenneth Research

Requirements	OpSens' Offer	FFR Requirements	TAVR Requirements
Sensor 2 nd generation Lowest-drift in the Industry	Accuracy in studies and clinical use	✓	✓
Guidewire Capabilities	One wire to Diagnose & Deliver	✓	✓
Sales Channels	Growing revenues Worldwide networks	✓	✓
Display Device	Several thousands of OptoMonitor in labs	✓	✓
Connectivity	Flawless connection	✓	✓

Coronary Artery Disease - Solid Business with Steady Growth
Market to reach \$1 billion by 2025¹

OptoWire, an optical guidewire that aims at improving the clinical outcomes of patients with coronary artery disease.



WORKHORSE PERFORMANCE: Pressure guidewire design, Excellent shape retention = control, torque, support for easy vessel access



ACCURACY: 2nd generation fiber optic sensor designed to provide lowest drift in the industry, consistent, repeatable measurements



CONNECTIVITY: Optical contact immune to procedural contaminants - Disconnect/reconnect with confidence to help in the diagnostic and delivery of stents on the same guidewire.

One wire from start to finish saves time and money

FAME 1² & 2, DEFER, COURAGE STUDIES
When the lesions of a patient are evaluated by physiological measurements (eg FFR) before a treatment is selected, rate of major cardiac events is considerably reduced.

1. Growth projected in Global FFR Market 2016-2020
2. Jan 15, 2009 NEJM 2009; 360:213-224
DOI: 10.1056/NEJMoa0807611

Industrial Segment

OpSens' technologies can answer needs in key markets. There is a positive sentiment around our Fabry-Perot technology (single-point measurement) in leading areas. This interest stems from the fact that traditional technologies do not perform as expected under certain conditions, opening avenues for OpSens' technology.

OpSens capitalizes on its adaptable technology and invests to offer applications to growing markets, like the monitoring of structures and various other applications in sectors such as aerospace, nuclear, power electronics and mining.

News:

OpSens Solutions receives advisory and funding support to develop optical-based fuel monitoring system for aerospace applications, including civil aircrafts with partner

OpSens Solution awarded a contract from RI Research Instruments GmbH for fiber optic pressure sensors for ITER (International Experimental Thermonuclear Reactor).

Contacts

Louis Laflamme, CPA, CA - President & CEO
louis.laflamme@opsens.com

Marie-Claude Poitras - Communications
marie-claude.poitras@opsens.com

OpSens Inc.
750 Blvd du Parc-Technologique
Quebec, QC G1P 4S3
418.781.0333